ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 2, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 2, 2011
News
FDA Unveils Inspections Database
By Erik Greb
FDA added a searchable database of inspection data to its website. The database lists the names and addresses of facilities that the agency inspected during fiscal years 2009 and 2010.
Mylan Plans Direct Entry Into Indian Market
By Amy Ritter
Mylan, a generic-drug manufacturer, announced that it will be rebranding its Hyderabad, India-based subsidiary, Matrix Laboratories, as Mylan.
Independent Expert Advises EMA on Benefit/Risk Communication
By Rich Whitworth
An independent report released by the European Medicines Agency highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines.
WHO Meets to Discuss Global Health Policy
By Patricia Van Arnum
During an eight-day series of meetings that concluded on May 24, 2011, the World Health Assembly passed 28 resolutions and adopted three decisions to guide the organization?s work and address global health issues.
Capgemini: Pharma Must Act Against Patient Noncompliance
By Stephanie Sutton
The pharmaceutical industry has been called to action by a new report that highlights the health and cost repercussions of patient noncompliance.
Week of June 2, 2011: Company and People Notes: Valeant agrees to acquire Sanitas Group; Geron makes several senior appointments; and More.
Valeant agrees to acquire Sanitas Group; Geron makes several senior appointments; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here